



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2024-25/BSE/195

Dated:05.06.2024

To,

Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Wednesday, 05th June 2024 **at 06:00 p.m. and concluded at 07:00 p.m.** discussed the following business: -

1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024 were approved and taken on record, a copy of which is enclosed, together with Independent Auditors' Report with unmodified opinion thereon, issued by the Statutory Auditors' of the Company and a declaration pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in respect of Audit Report for the year ended March 31, 2024.

The copy of Audited Financial Results (Standalone and Consolidated) as adopted and approved by the Board of Directors and Auditor's report thereon are attached herewith for your ready reference.

You are requested to kindly take the same on record.

Yours Faithfully,

FOR SANDU PHARMACEUTICALS LTD.

Pratika Mhambray
Company Secretary



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



SANDU PHARMACEUTICALS LIMITED

Standalone Statement of Profit and Loss for the Period ended 31st March, 2024

Particulars	3 Months ended	Preceding 3 Months Ended	Corresponding 3 Months ended	Year ended	Year ended
	31 st March 2024	31 St December, 2023	31st March 2023	31st March 2024	31st March 2023
	Audited	Unaudited	Audited	Audited	Audited
INCOME					
Revenue From Operations	1,559.77	1,742.87	1,526.49	6,728.07	6,534.90
Other Income	30.66	2.67	4.48	42.13	32.72
Total Income	1,590.43	1,745.57	1,530.97	6,770.20	6,567.62
EXPENSES					
Cost of materials consumed	284.19	241.70	317.01	985.26	1,113.24
Purchases of Stock-in-Trade	559.49	641.40	424.19	2,108.28	2,313.46
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(223.71)	(20.44)	(118.88)	163.48	(307.62)
Employee benefits expense	246.99	253.38	307.33	1,007.32	1,109.53
Finance costs	0.73	1.76	1.55	6.31	7.96
Depreciation and amortization expense	18.65	14.17	13.41	58.33	51.66
Other expenses	632.38	575.74	548.57	2,234.00	2,057.35
Total expenses	1,518.71	1,707.70	1,493.18	6,562.97	6,345.59
Profit/(loss) before exceptional items and tax	71.72	37.84	37.79	207.24	222.03
Exceptional Items / Prior Period Adjustment			-		-
PROFIT/(LOSS) BEFORE TAX	71.72	37.84	37.79	207.24	222.03
Tax expense:					
Current tax	21.05	10.72	10.14	58.71	62.82
Deferred tax	(8.57)	6.42	0.28	2.46	3.41
Short / (Excess) Tax Provision					3.39
PROFIT (LOSS) FOR THE PERIOD	59.24	20.70	27.38	146.07	152.41
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified to profit or loss in Subsequent Periods :					
Remeasurement gains/(losses) on post employment defined benefit plans	(11.96)	-	0.20	(11.96)	0.20
Fair value changes of investments	23.22	17.75	16.82	78.90	63.93
Income tax relating to items that will not be reclassified to profit or loss	0.75	(3.99)	(1.93)	(5.45)	(7.17)
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	12.01	13.76	15.10	61.49	56.96
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	71.25	34.45	42.48	207.56	209.36
Paid Up Equity Capital (Face Value of Rs 10/- Per share)	966.10	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE					
Basic	0.50	0.21	0.27	1.51	1.62
Diluted	0.50	0.21	0.27	1.51	1.62

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai
Date :- 05/06/2024

SANDU PHARMACEUTICALS LIMITED
Standalone Balance Sheet as at 31st, March, 2024

PARTICULARS	(Rs in lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
	Amount (₹)	Amount (₹)
ASSETS		
Non-current assets		
Property, Plant and Equipment	840.59	721.84
Right of use assets	943.73	934.79
Capital Work In Progress	-	41.96
Other Intangible Assets	3.49	5.05
Financial Assets		
Investments	1,042.70	965.61
Other Financial Asset	181.60	193.87
	3,012.11	2,863.12
Current assets		
Inventories	1,225.06	1,432.56
Financial Assets		
Trade receivables	486.83	479.22
Cash and cash equivalents	99.55	226.56
Bank balances other than 9 (a) above	20.22	2.00
Other current assets	397.86	413.17
	2,229.51	2,553.51
	5,241.62	5,416.63
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	966.10	966.10
Other Equity	3,093.43	2,958.34
	4,059.53	3,924.44
Non-current liabilities		
Financial Liabilities		
Finance Lease obligations	6.03	-
Deferred tax liabilities (Net)	112.11	104.20
	118.14	104.20
Current liabilities		
Financial Liabilities		
Finance Lease obligations	0.30	-
Trade payables Due to :		
Dues to Micro & small Enterprises	30.43	118.14
Other Than small & micro enterprises	388.95	721.64
Other Financial Liabilities	14.71	9.26
Other current liabilities	131.60	131.64
Provisions	497.96	407.32
	1,063.95	1,387.99
	5,241.62	5,416.63

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai
Date :- 05/06/2024

SANDU PHARMACEUTICALS LIMITED
Statement of changes in equity for the Period ended 31st March, 2024

A. Equity Share Capital & Reconciliation of number of shares outstanding at the beginning of the year

Particulars	As at 31 st March, 2024		As at 31st March, 2023	
	Number of shares	Amount (₹)	Number of shares	Amount (₹)
Opening Balance	96.60	966.10	88.10	881.07
Add: Shares Issued during the year	-	-	8.50	85.03
Closing Balance	96.60	966.10	96.60	966.10

B. OTHER EQUITY

Particulars	Share Application Pending Allotment/Money received against share warrants (₹)	Reserves and Surplus (₹)			Other Comprehensive Income (₹)			Total (₹)
		General Reserve	Retained Earnings	Securities Premium reserve account	Equity Instruments through Other Comprehensive Income	Revaluation Surplus	Other Comprehensive Income - Employee Benefits	
Balance as at 31st March, 2022	43.98	950.28	667.70	184.91	9.40	897.99	12.14	2,766.39
Profit for the Year	-	-	152.39	-	-	-	-	152.39
Other Comprehensive Income (Net of tax) Transfer to retained earnings	-	-	-	-	-	-	0.20	58.71
Dividend Paid	-	-	13.80	-	-	(13.80)	-	-
Allotment under preferential allotments scheme	(43.98)	-	(66.08)	-	-	-	-	(66.08)
Transfer to retained earnings on disposal of Equity Instruments	-	-	-	90.90	-	-	-	46.92
Amount Transferred on account of Deferred Tax on Sale of Investments	-	-	1.75	-	(1.75)	-	-	-
Balance as at 31st March, 2023	-	950.28	769.56	275.81	66.16	884.19	12.34	2,958.33
Profit for the Year	-	-	146.07	-	-	-	-	146.07
Other Comprehensive Income (Net of tax) Transfer to retained earnings	-	-	-	-	-	-	(8.63)	61.49
Dividend Paid	-	-	13.80	-	-	(13.80)	-	-
Allotment under Preferential Allotments Scheme	-	-	(72.46)	-	-	-	-	(72.46)
Transfer to retained earnings on disposal of Equity Instruments	-	-	-	-	-	-	-	-
Amount Transferred on account of Deferred Tax on Sale of Investments	-	-	1.51	-	(1.51)	-	-	-
Deferred Tax on Sale of Investments	-	-	0.30	-	(0.30)	-	-	-
Balance as at 31st March, 2024	-	950.28	858.79	275.81	134.47	870.39	3.71	3,093.42

For Sandu Pharmaceuticals Ltd
Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai
Date :- 05/06/2024

SANDU PHARMACEUTICALS LIMITED
Standalone Statement of Cash Flow for the year ended 31st March, 2024

Particulars	Year ended 31st March, 2024		Year ended 31st March, 2023	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		207.24		222.03
Adjustments for:				
Depreciation and amortisation expenses	58.33		51.66	
Finance costs	6.31		7.96	
Interest income	(15.93)		(15.80)	
Allowance for doubtful debts / expected credit losses - trade receivable	4.27		3.76	
Re-measurement gains/losses on employee defined benefit plans	(11.96)		0.20	
		41.01		47.78
Operating profit / (loss) before changes in operating assets & liabilities		248.25		269.81
Changes in operating assets				
(increase) / decrease in inventories	207.50		(305.34)	
(increase) / decrease in Trade receivables	(11.87)		(83.84)	
(increase) / decrease in other operating assets	65.19		(9.59)	
Changes in operating liabilities				
(increase) / decrease in trade payables	(420.40)		157.99	
(increase) / decrease in other operating liabilities	37.35	(122.23)	63.03	(177.75)
Cash Generated from operation		126.01		92.06
Income Tax Paid		(49.88)		(69.95)
Net Cash flow from Operating activities		76.13		22.12
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	(142.51)		(106.88)	
Fixed deposits placed with banks	-		133.00	
Interest received	(5.95)		15.80	
Dividend income from equity instruments designated at FVTOCI	15.93		-	
Purchases of Mutual fund / Shares designated at FVTOCI	101.82		(40.00)	
Sandu Phytoceuticals P Ltd	-		(1.00)	
Proceeds from Sales of Mutual Funds /Shares	(100.00)		51.74	
Net cash flow from / (used in) investing activities (B)		(130.71)		52.66
C. Cash flow from financing activities				
Finance lease obligations	6.33		-	
Finance cost	(6.31)		(7.96)	
Proceeds from Issue of Equity Share Capital	-		131.95	
Dividend Paid	(72.46)		(66.08)	
Net cash flow from / (used in) financing activities (C)		(72.43)		57.91
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(127.01)		132.69
Cash and cash equivalents at the beginning of the year		226.55		93.86
Cash and cash equivalents at the end of the year		99.55		226.55

Notes:

1. The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
2. For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Reconciliation of cash and cash equivalents with the balance sheet :

Particulars	31st March, 2024	31st March, 2023
As per Balance Sheet -note 11(a)	99.55	226.55
Balance as per statement of cash flows	99.55	226.55

Place :- Mumbai
Date :- 05/06/2024



For Sandu Pharmaceuticals Ltd


Umesh Sandu
Managing Director
DIN :- 01132141

1. The Above results published in accordance with regulation 33 no of the SEBI(Listing Obligations & Disclosures Requirements), 2015. The financial results are in accordance with the Indian Accounting Standards (IND AS) as prescribed u/s 133 of the Companies Act , 2013 Read with rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 & Companies (Indian Account Standard) Amendments rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. 'Ayurvedic Property Medicine'. Accordingly as per IND AS – 108. The company as only one business segment and hence segment information as not been separately disclosed.
3. Company as formed a hundred percent subsidiary company in the name of Sandu Phytocetucials pvt ltd ,new company was registered on date 27th July, 2022. The nature of business of the company is to Manufacture Ayurvedic – Herbal extract and Medicine extract etc.

Company has not started the production activity yet and the expense related to formation has been considered in the consolidated financials for the year ended 31st March 2024.

4. The figure for the Quarter ended 31st March 2024. And 31st March 2023 are the balancing figures between the audited figures in respect in the full financial year and the published year to date upto the 3rd Quarter of their respective financial year.
5. The above results were reviewed and recommended by audit committee and approved by the board of directors held on 5th June 2024.
6. Figures for the previous periods have been classified/ regroup wherever necessary.

Date : 5th June 2024

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN No: - 01132141

SANDU PHARMACEUTICALS LIMITED

Consolidated Statement of Profit and Loss for the Period ended 31st March, 2024

Particulars	(Rs in lakhs)				
	3 Months ended	Preeceding 3 Months Ended	Corresponding 3 Months ended	Year ended	Year ended
	31 st March 2024	31 St December, 2023	31st March 2023	31st March 2024	31st March 2023
	Audited	Unaudited	Audited	Audited	Audited
INCOME					
Revenue From Operations	1,559.77	1,742.87	1,526.49	6,728.07	6,534.90
Other Income	30.89	2.67	4.48	42.36	32.72
Total Income	1,590.66	1,745.54	1,530.97	6,770.43	6,567.62
EXPENSES					
Cost of materials consumed	284.20	241.70	317.01	985.26	1,113.24
Purchases of Stock-in-Trade	559.49	641.40	424.19	2,108.28	2,313.46
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	(223.71)	(20.44)	(118.88)	163.48	(307.62)
Employee benefits expense	246.99	253.38	307.33	1,007.32	1,109.53
Finance costs	0.73	1.76	1.55	6.31	7.96
Depreciation and amortization expense	18.65	14.17	13.44	58.33	51.68
Other expenses	632.40	575.79	548.72	2,234.17	2,057.68
Total expenses	1,518.74	1,707.76	1,493.35	6,563.14	6,345.93
Profit/(loss) before exceptional items and tax	71.94	37.79	37.62	207.29	221.68
Exceptional Items / Prior Period Adjustment			-		-
PROFIT/(LOSS) BEFORE TAX	71.94	37.79	37.62	207.29	221.68
Tax expense:					
Current tax	21.05	10.72	10.17	58.71	62.85
Deferred tax	(8.57)	6.42	0.28	2.46	3.42
Short / (Excess) Tax Provision					3.39
PROFIT (LOSS) FOR THE PERIOD	59.46	20.64	27.17	146.12	152.02
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified to profit or loss in Subsequent Periods :					
Remeasurement gains/(losses) on post employment defined benefit plans	(11.96)	-	0.20	(11.96)	0.20
Fair value changes of investments	23.22	17.75	16.82	78.90	63.93
Income tax relating to items that will not be reclassified to profit or loss	0.75	(3.99)	(1.93)	(5.45)	(7.17)
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	12.01	13.76	15.10	61.49	56.96
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	71.47	34.40	42.27	207.61	208.97
Paid Up Equity Capital (Face Value of Rs 10/- Per share)	966.10	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE					
Basic	0.62	0.21	0.26	1.51	1.61
Diluted	0.62	0.21	0.26	1.51	1.61

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai

Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Pilerne, Marra, Saligao, Bardez, Goa - 403511.

Tel.: +91 832 6715000 / 05 / 36 / 2407475, E-mail: sandupharma@sandu.in

CIN:L24233GA1985PLC001587



SANDU PHARMACEUTICALS LIMITED
Consolidated Balance Sheet as at 31st, March, 2024

PARTICULARS	(Rs in lakhs)	
	As at 31st March, 2024	As at 31st March, 2023
	Amount (`)	Amount (`)
ASSETS		
Non-current assets		
Property, Plant and Equipment	840.59	721.84
Right of use assets	943.73	934.79
Capital Work In Progress	-	41.96
Other Intangible Assets	3.49	5.05
Financial Assets		
Investments	1,041.70	964.61
Other Financial Asset	181.60	193.87
	3,011.11	2,862.12
Current assets		
Inventories	1,225.06	1,432.56
Financial Assets		
Trade receivables	486.83	479.22
Cash and cash equivalents	100.41	227.56
Bank balances other than 9 (a) above	20.22	2.00
Other current assets	397.86	413.17
	2,230.37	2,554.50
	5,241.49	5,416.63
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	966.10	966.10
Other Equity	3,093.16	2,958.01
	4,059.26	3,924.11
Non-current liabilities		
Financial Liabilities		
Finance Lease obligations	6.03	-
Deferred tax liabilities (Net)	112.11	104.20
	118.14	104.20
Current liabilities		
Financial Liabilities		
Finance Lease obligations	0.30	-
Trade payables Due to :		
Dues to Micro & small Enterprises	30.43	118.14
Other Than small & micro enterprises	389.09	721.64
Other Financial Liabilities	14.71	9.26
Other current liabilities	131.60	131.64
Provisions	497.96	407.65
	1,064.09	1,388.32
	5,241.49	5,416.63

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141



Place :- Mumbai
Date :- 05/06/2024

Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Pilerne, Marra, Saligao, Bardez, Goa - 403511.
Tel.: +91 832 6715000 / 05 / 36 / 2407475, E-mail: sandupharma@sandu.in

CIN:L24233GA1985PLC001587

SANDU PHARMACEUTICALS LIMITED
Consolidated of changes in equity for the period ended 31st March, 2024

A. Equity Share Capital & Reconciliation of number of shares outstanding at the beginning of the year

Particulars	As at 31 st March, 2024		As at 31st March, 2023	
	Number of shares	Amount (₹)	Number of shares	Amount (₹)
Opening Balance	96,60,990	966.10	88,10,664	881.07
Add: Shares Issued during the year	-	-	8,50,326	85.03
Closing Balance	96,60,990	966.10	96,60,990	966.10

B. OTHER EQUITY

Particulars	Share Application Pending Allotment/Money received against share warrants (₹)	Reserves and Surplus (₹)			Other Comprehensive Income (₹)			Total (₹)
		General Reserve	Retained Earnings	Securities Premium reserve account	Equity Instruments through Other Comprehensive Income	Revaluation Surplus	Other Comprehensive Income - Employee Benefits	
Balance as at 31st March, 2022	43.98	950.28	667.71	184.91	9.40	897.99	12.14	2,766.42
Profit for the Year	-	-	152.05	-	-	-	-	152.05
Other Comprehensive Income (Net of tax)	-	-	-	-	58.51	-	-	58.51
Transfer to retained earnings	-	-	13.80	-	-	(13.80)	0.20	0.20
Dividend Paid	-	-	(66.08)	-	-	-	-	(66.08)
Allotment under preferential allotments scheme	(43.98)	-	-	-	-	-	-	-
Transfer to retained earnings on disposal of Equity Instruments	-	-	-	90.90	-	-	-	90.90
Amount Transferred on account of Deferred Tax on Sale of Investments	-	-	1.75	-	(1.75)	-	-	-
Balance as at 31st March, 2023	-	950.28	769.22	275.82	66.16	884.19	12.34	2,958.01
Profit for the Year	-	-	146.12	-	-	-	-	146.12
Other Comprehensive Income (Net of tax)	-	-	-	-	70.12	-	(8.63)	61.49
Transfer to retained earnings	-	-	13.80	-	-	(13.80)	-	-
Dividend Paid	-	-	(72.46)	-	-	-	-	(72.46)
Allotment under Preferential Allotments Scheme	-	-	-	-	-	-	-	-
Transfer to retained earnings on disposal of Equity Instruments	-	-	-	1.51	(1.51)	-	-	-
Amount Transferred on account of Deferred Tax on Sale of Investments	-	-	0.30	-	(0.30)	-	-	-
Balance as at 31st March, 2024	-	950.28	858.51	275.82	134.47	870.38	3.71	3,093.16

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN :- 01132141

Place :- Mumbai
Date :- 05/06/2024

SANDU PHARMACEUTICALS LIMITED

Consolidated Statement of Cash Flow for the year ended 31st March, 2024

Particulars	Year ended 31st March, 2024		Year ended 31st March, 2023	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		207.29		221.67
Adjustments for:				
Depreciation and amortisation expenses	58.33		51.68	
Finance costs	6.31		7.96	
Interest income	(15.93)		(15.80)	
Allowance for doubtful debts / expected credit losses - trade receivable	4.27		3.76	
Re-measurement gains/losses on employee defined benefit plans	(11.96)		0.20	
		41.01		47.80
Operating profit / (loss) before changes in operating assets & liabilities		248.31		269.48
Changes in operating assets				
(increase) / decrease in inventories	207.50		(305.34)	
(increase) / decrease in Trade receivables	(11.87)		(83.84)	
(increase) / decrease in other operating assets	65.19		(9.59)	
Changes in operating liabilities				
(increase) / decrease in trade payables	(420.59)		157.99	
(increase) / decrease in other operating liabilities	37.35	(122.42)	63.36	(177.42)
Cash Generated from operation		125.88		92.07
Income Tax Paid		(49.88)		(69.95)
Net Cash flow from Operating activities		76.00		22.12
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	(142.51)		(106.88)	
Fixed deposits placed with banks	-		133.00	
Interest received	(5.95)		15.80	
Dividend income from equity instruments designated at FVTOCI	15.93		-	
Purchases of Mutual fund / Shares designated at FVTOCI	101.82		(40.00)	
Proceeds from Sales of Mutual Funds /Shares	(100.00)		51.74	
Net cash flow from / (used in) investing activities (B)		(130.71)		53.67
C. Cash flow from financing activities				
Finance lease obligations	6.33		-	
Finance cost	(6.31)		(7.96)	
Proceeds from Issue of Equity Share Capital	-		131.95	
Dividend Paid	(72.46)		(66.08)	
Net cash flow from / (used in) financing activities (C)		(72.43)		57.91
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		(127.14)		133.70
Cash and cash equivalents at the beginning of the year		227.55		93.86
Cash and cash equivalents at the end of the year		100.41		227.55

Notes:

- The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
- For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Reconciliation of cash and cash equivalents with the balance sheet :

Particulars	31st March, 2024	31st March, 2023
As per Balance Sheet -note 11(a)	100.41	227.55
Balance as per statement of cash flows	100.41	227.55

For Sandu Pharmaceuticals Ltd




Umesh Sandu
Managing Director
DIN :- 01132141

Place :- Mumbai
Date :- 05/06/2024

1. The Above results published in accordance with regulation 33 no of the SEBI (Listing Obligations & Disclosures Requirements), 2015. The financial results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under section 133 of the Companies Act , 2013 Read with rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 & Companies (Indian Account Standard) Amendments rules, 2017.
2. Company as formed a hundred percent subsidiary company in the name of Sandu Phytocetucials Pvt Ltd, new company was registered on date 27th July, 2022. The nature of business of the company is to Manufacture Ayurvedic – Herbal extract and Medicine extract etc.

Company has not started the production activity yet and the expense related to formation has been considered in the consolidated financials for the year ended 31st March 2024.

3. The Above Consolidated financial results of Sandu Pharmaceuticals Ltd , (“The Holding Company”), It’s subsidiaries (The Holding Company and its subsidiaries together referred to as “The Group”), have been reviewed by the audit committee and approved by Board of Directors at its meeting held on June 05 , 2024.
4. The figure for the Quarter ended 31st March 2024. And 31st March 2023 are the balancing figures between the audited figures in respect in the full financial year and the published year to date up to the 3rd Quarter of their respective financial year.
5. Figures for the previous periods have been classified/ regroup wherever necessary

Date : 5th June 2024

For Sandu Pharmaceuticals Ltd



Umesh Sandu
Managing Director
DIN No: - 01132141



Dileep & Prithvi

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Year to date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,

**The Board of Director of,
SANDU PHARMACEUTICALS LIMITED**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statements of standalone Financial Results of **SANDU PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and year ended on March 31, 2024 ('the statement') being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- a. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- b. Gives a true and fair view in conformity with the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended on March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013(the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Management Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the Audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate 'internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain Professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company have adequate financial control reference to Financial Statement in place and the operating effectiveness of such control.





Dileep & Prithvi

CHARTERED ACCOUNTANTS

- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

- a. The Statement dealt with by this report has been prepared for the express purpose of filing with BSE Limited. This Statement is based on and should be read with the financial results of the company for the quarter and year ended March 31, 2024 on which we issued an unmodified audit opinion vide our report dated June 5, 2024.
- b. The Statement includes the results for the quarter ended March 31, 2024, being the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to December 31, 2023 being the date of the end of the third quarter of the current financial year.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W


Himmat Mali

(Partner)
Membership Number: 183378
UDIN: 24183378BKDAYA4279
Place: Mumbai
Date: June 5, 2024





Dileep & Prithvi

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Year to date Consolidated Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,

**The Board of Director of,
SANDU PHARMACEUTICALS LIMITED**

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statements of consolidated Financial Results of **SANDU PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and year ended on March 31, 2024 ("the statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, these Consolidated financial results:

- a. Includes the result of the following entity:
 - a. Sandu Pharmaceuticals Limited ("The Parent")
 - b. Sandu Phytoceuticals Private Limited ("Subsidiary Company")
- b. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- c. Gives a true and fair view in conformity with the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended on March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013(the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the consolidated financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Management Responsibilities for the Consolidated Financial Results

These quarterly financial results as well as the year to date consolidated financial results have been prepared on the basis of the consolidated audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate 'internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain Professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company have adequate financial control reference to Financial Statement in place and the operating effectiveness of such control.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.





Dileep & Prithvi

d. H. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- e. Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

- a. The Statement dealt with by this report has been prepared for the express purpose of filing with BSE Limited. This Statement is based on and should be read with the financial results of the company for the quarter and year ended March 31, 2024 on which we issued an unmodified audit opinion vide our report dated June 5, 2024.
- b. The Statement includes the audited financial result and other financial information of subsidiary which reflect total revenue of Nil, total net profit of 21,000/- and 5,599/- for the quarter and year ended March 31, 2024, respectively, whose financial results have not been audited by us. These financial results have been audited by other auditor whose report have been furnished to us by the management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of the other auditor and the procedure performed by us as stated in paragraph 3 above.
Our conclusion on the statement is not modified in respect of the above matter.
- c. The Statement includes the results for the quarter ended March 31, 2024, being the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to December 31, 2023 being the date of the end of the third quarter of the current financial year.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W


Himmat Mali

(Partner)
Membership Number: 183378
UDIN: 24183378BKDAYB6650
Place: Mumbai
Date: June 5, 2024





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2024-25/BSE/189

Dated:05.06.2024

To,

Bombay Stock Exchange Ltd,
PherojshahJeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Scrip Code: 524703

Sub: Declaration regarding Audit Report on Standalone & Consolidated Financial Results for the Quarter and Year ended 31st March 2024 with unmodified opinion of the Independent Auditors.

Dear Sir,

We hereby confirm and declare that the Statutory Auditors of the Company i.e M/s Dileep and Prithvi, Chartered Accountants, Mumbai (Firm No:122290W), have issued the Audit Report on Standalone & Consolidated Financial Results of the Company for the Quarter and Year ended 31st March 2024 with Unmodified opinion.

We submit this declaration as required under the provisions of the Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) 2015 as amended and circular CIR/CFD/CMD/56/2016 May, 2016 issued by SEBI.

You are requested to take the above letter on record.

Yours Faithfully

For Sandu Pharmaceuticals Limited

Umesh B Sandu
Managing Director
DIN: 01132141



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref:Corp.sec/BSE/2024-25/188

Dated:30.05.2024

To,
Department of Corporate Services
Bombay Stock Exchange Limited,
Phirojshah Jeejobhoy tower, Dalal
Street,
Mumbai-400001.

Sub: Reporting of Initial Disclosure to be made by entities identified as Large Corporates.

Sr No	Particulars	Details
1.	Name of the Company	SANDU PHARMACEUTICALS LIMITED
2	BSE Scrip Code	524703
3	NSE Symbol	NA
4	CIN	L24233GA1985PLC001587
5	Financial Year (From-To)	01 st April 2023 to 31 st March 2024
6	Outstanding Qualified Borrowings at the start of the Financial Year (Rs in Lakhs)	NIL
7	Outstanding Qualified Borrowings at the end of the Financial Year (Rs in Lakhs)	NIL
8	Highest credit rating of the Company relating to the unsupported bank borrowings or plain vanilla bonds which have no structuring /support built in	NA
9	Incremental borrowings done during the Year (qualified borrowings) (Rs . in lakhs)	NIL
10	Borrowings by way of issuance of debt securities during the year (Rs in Lakhs)	NIL
11	Name of Stock Exchange in which the fine shall be in paid in case of shortfall in the required borrowings under the framework	BSE



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI Circular No. SEBI/HO/DDHS/DDHS-PODI/P/CIR/2023/172 dated 19th October 2023 read with Chapter XII of updated SEBI Operational Circular dated 13th April 2022 as amended.

The above disclosure shall be taken on record as an enclosure to the Audited Financial Results for the Audited Financial Results for the Financial Year ended 31st March 2024.

For Sandu Pharmaceuticals Limited

Pratika Mhambray
Company Secretary
Cont No:7208025419

Vijay Kajarekar
Chief Financial Officer
Cont No:9049919108

Dated:30.05.2024



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B; No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in

